Cargando…
Withdrawal notice to: “Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data” [Heliyon 9, (2023) 16897]
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361350/ https://www.ncbi.nlm.nih.gov/pubmed/37484247 http://dx.doi.org/10.1016/j.heliyon.2023.e17229 |
| _version_ | 1785076199028948992 |
|---|---|
| author | Shen, Chong Fu, Chong Suo, Yong Li, Kai Zhang, Zhe Yang, Shaobo Zhang, Yu Lin, Yuda Li, Zhi Wu, Zhouliang Huang, Shiwang Chen, Houyuan Fan, Zhenqian Hu, Hailong |
| author_facet | Shen, Chong Fu, Chong Suo, Yong Li, Kai Zhang, Zhe Yang, Shaobo Zhang, Yu Lin, Yuda Li, Zhi Wu, Zhouliang Huang, Shiwang Chen, Houyuan Fan, Zhenqian Hu, Hailong |
| author_sort | Shen, Chong |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10361350 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103613502023-07-22 Withdrawal notice to: “Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data” [Heliyon 9, (2023) 16897] Shen, Chong Fu, Chong Suo, Yong Li, Kai Zhang, Zhe Yang, Shaobo Zhang, Yu Lin, Yuda Li, Zhi Wu, Zhouliang Huang, Shiwang Chen, Houyuan Fan, Zhenqian Hu, Hailong Heliyon Corrigendum Elsevier 2023-06-14 /pmc/articles/PMC10361350/ /pubmed/37484247 http://dx.doi.org/10.1016/j.heliyon.2023.e17229 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Corrigendum Shen, Chong Fu, Chong Suo, Yong Li, Kai Zhang, Zhe Yang, Shaobo Zhang, Yu Lin, Yuda Li, Zhi Wu, Zhouliang Huang, Shiwang Chen, Houyuan Fan, Zhenqian Hu, Hailong Withdrawal notice to: “Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data” [Heliyon 9, (2023) 16897] |
| title | Withdrawal notice to: “Pan-cancer analyses of clinical prognosis,
immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data”
[Heliyon 9, (2023) 16897] |
| title_full | Withdrawal notice to: “Pan-cancer analyses of clinical prognosis,
immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data”
[Heliyon 9, (2023) 16897] |
| title_fullStr | Withdrawal notice to: “Pan-cancer analyses of clinical prognosis,
immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data”
[Heliyon 9, (2023) 16897] |
| title_full_unstemmed | Withdrawal notice to: “Pan-cancer analyses of clinical prognosis,
immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data”
[Heliyon 9, (2023) 16897] |
| title_short | Withdrawal notice to: “Pan-cancer analyses of clinical prognosis,
immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data”
[Heliyon 9, (2023) 16897] |
| title_sort | withdrawal notice to: “pan-cancer analyses of clinical prognosis,
immune infiltration, and immunotherapy efficacy for trpv family using multi-omics data”
[heliyon 9, (2023) 16897] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361350/ https://www.ncbi.nlm.nih.gov/pubmed/37484247 http://dx.doi.org/10.1016/j.heliyon.2023.e17229 |
| work_keys_str_mv | AT shenchong withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT fuchong withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT suoyong withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT likai withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT zhangzhe withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT yangshaobo withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT zhangyu withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT linyuda withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT lizhi withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT wuzhouliang withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT huangshiwang withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT chenhouyuan withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT fanzhenqian withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 AT huhailong withdrawalnoticetopancanceranalysesofclinicalprognosisimmuneinfiltrationandimmunotherapyefficacyfortrpvfamilyusingmultiomicsdataheliyon9202316897 |